Jiangsu Hengrui Medicine
600276.SS
#456
Rank
NZ$90.87 B
Marketcap
NZ$13.69
Share price
-1.20%
Change (1 day)
19.27%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): NZ$1.99 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$4.19 Billion. In 2024 the company made an earning of NZ$1.67 Billion, an increase over its 2023 earnings that were of NZ$1.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.99 B18.78%
2024 NZ$1.67 B50.59%
2023 NZ$1.11 B11.35%
2022 NZ$1.00 B-13.82%
2021 NZ$1.16 B-34.16%
2020 NZ$1.76 B16.28%
2019 NZ$1.51 B32.92%
2018 NZ$1.14 B20.82%
2017 NZ$0.94 B23.8%
2016 NZ$0.76 B11.25%
2015 NZ$0.68 B39.52%
2014 NZ$0.49 B20.71%
2013 NZ$0.40 B11.46%
2012 NZ$0.36 B29.6%
2011 NZ$0.28 B31.28%
2010 NZ$0.21 B27.89%
2009 NZ$0.16 B5.84%
2008 NZ$0.15 B79.89%
2007 NZ$88.28 M32.93%
2006 NZ$66.41 M38.14%
2005 NZ$48.07 M21.56%
2004 NZ$39.54 M13.95%
2003 NZ$34.7 M38.06%
2002 NZ$25.13 M